Intravenous Golimumab After Infliximab Failure in Hidradenitis Suppurativa: A Retrospective Cohort Study
Description
This dataset presents longitudinal changes in clinical and inflammatory outcomes following initiation of intravenous golimumab (IVgol) in patients with hidradenitis suppurativa (HS) who had previously failed infliximab due to infliximab-associated anaphylaxis or anti-infliximab antibody formation. We hypothesized that IVgol, a fully human TNF-α inhibitor with reduced immunogenicity, would produce meaningful and durable reductions in disease severity, pain, and systemic inflammation in this refractory population. Data were collected via retrospective chart review at a single academic HS center and include six outcome measures: HS-Physician Global Assessment (HS-PGA, 0–5), numerical rating scale pain score (NRS-pain, 0–10), interleukin-6 (IL-6, pg/mL), erythrocyte sedimentation rate (ESR, mm/h), C-reactive protein (CRP, mg/L), and white blood cell count (WBC, ×10⁹ cells/L). Each figure displays mean values at baseline and months 1, 6, and 12. All 30 patients had baseline and Month 1 data available; 17 had available Month 6 and Month 12 data and are represented at those timepoints. Across all six outcomes, IVgol was associated with reductions from baseline at Month 1, with sustained or progressive improvement through Month 12 among patients with available follow-up data. HS-PGA and ESR showed the most consistent trajectories, while CRP exhibited transient visit-to-visit variability at Month 6 consistent with the episodic, flare-driven nature of HS rather than treatment failure. WBC demonstrated a delayed pattern of significance, with statistically significant reductions emerging at months 6 and 12. Taken together, these figures provide objective clinical and biomarker evidence supporting IVgol as an effective alternative weight-based therapy for HS patients who cannot continue infliximab.
Files
Institutions
- Weill Cornell MedicineNew York, New York